6-111310079-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 1P and 8B. PP2BP4_StrongBS2
The NM_001372078.1(REV3L):c.8816G>A(p.Arg2939Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000475 in 1,557,462 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000048 ( 0 hom. )
Consequence
REV3L
NM_001372078.1 missense
NM_001372078.1 missense
Scores
4
2
12
Clinical Significance
Conservation
PhyloP100: 7.69
Genes affected
REV3L (HGNC:9968): (REV3 like, DNA directed polymerase zeta catalytic subunit) The protein encoded by this gene represents the catalytic subunit of DNA polymerase zeta, which functions in translesion DNA synthesis. The encoded protein can be found in mitochondria, where it protects DNA from damage. Defects in this gene are a cause of Mobius syndrome. [provided by RefSeq, Jan 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -7 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), REV3L. . Gene score misZ 2.4677 (greater than the threshold 3.09). Trascript score misZ 3.98 (greater than threshold 3.09). GenCC has associacion of gene with Mobius syndrome.
BP4
Computational evidence support a benign effect (MetaRNN=0.054683268).
BS2
High AC in GnomAd4 at 6 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
REV3L | NM_001372078.1 | c.8816G>A | p.Arg2939Gln | missense_variant | 30/32 | ENST00000368802.8 | NP_001359007.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
REV3L | ENST00000368802.8 | c.8816G>A | p.Arg2939Gln | missense_variant | 30/32 | 1 | NM_001372078.1 | ENSP00000357792.3 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 151910Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
151910
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000121 AC: 26AN: 215234Hom.: 0 AF XY: 0.000111 AC XY: 13AN XY: 116664
GnomAD3 exomes
AF:
AC:
26
AN:
215234
Hom.:
AF XY:
AC XY:
13
AN XY:
116664
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000484 AC: 68AN: 1405434Hom.: 0 Cov.: 30 AF XY: 0.0000489 AC XY: 34AN XY: 695930
GnomAD4 exome
AF:
AC:
68
AN:
1405434
Hom.:
Cov.:
30
AF XY:
AC XY:
34
AN XY:
695930
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000395 AC: 6AN: 152028Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74304
GnomAD4 genome
AF:
AC:
6
AN:
152028
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74304
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
19
Asia WGS
AF:
AC:
6
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 20, 2024 | The c.8816G>A (p.R2939Q) alteration is located in exon 30 (coding exon 30) of the REV3L gene. This alteration results from a G to A substitution at nucleotide position 8816, causing the arginine (R) at amino acid position 2939 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
T;T;.;T;.
Eigen
Uncertain
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;.;D;D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Benign
T
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N;.
REVEL
Benign
Sift
Benign
T;T;T;T;.
Sift4G
Benign
T;T;T;T;T
Polyphen
D;D;.;D;.
Vest4
MutPred
Loss of phosphorylation at S2941 (P = 0.0692);Loss of phosphorylation at S2941 (P = 0.0692);.;Loss of phosphorylation at S2941 (P = 0.0692);.;
MVP
MPC
1.7
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at